Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 4/20 | 0.62 |
| ▸ | GRM2 | Q14416 | 9/20 | 0.53 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.53 |
| ▸ | GRM6 | O15303 | 7/20 | 0.53 |
| ▸ | GRM5 | P41594 | 5/20 | 0.53 |
| ▸ | GRM3 | Q14832 | 4/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25660648 | 1.00 | GRM1 (0.62) | GRM1GRM2GRM4GRM6GRM5 | |
| SCHEMBL10577620 | 1.00 | GRM1 (0.62) | GRM1GRM2GRM4GRM6GRM5 | |
| SCHEMBL5522614 | 0.81 | GRM1 (0.42) | GRM1GRM2GRM4GRM6GRM5 | |
| SCHEMBL25910070 | 0.81 | GRM1 (0.42) | GRM1GRM2GRM4GRM6GRM5 | |
| SCHEMBL13319986 | 0.77 | GRM1 (1.00) | GRM1GRM2GRM4GRM6GRM5 | |
| SCHEMBL6738759 | 0.77 | GRM1 (1.00) | GRM1GRM2GRM4GRM6GRM5 | |
| SCHEMBL669419 | 0.74 | GRM2 (0.47) | GRM1GRM2GRM4GRM6GRM5 | |
| SCHEMBL3375726 | 0.74 | GRM1 (0.38) | GRM1GRM2GRM4GRM6GRM5 | |
| SCHEMBL32674074 | 0.74 | GRM1 (0.38) | GRM1GRM2GRM4GRM6GRM5 | |
| SCHEMBL10093291 | 0.70 | GRM1 (0.35) | GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4851035-A | Composition for inhibition of ethylene production in plants | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, STANFORD UNIVERSITY (US) | 1989-07-25 | — | — | US | claimed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023044171-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| EP-2606038-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2016-01-13 | — | — | EP | disclosed |
| US-8765944-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2606038-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20120213729-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| WO-2012024373-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-23 | — | — | WO | disclosed |
| US-4851035-A | Composition for inhibition of ethylene production in plants | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, STANFORD UNIVERSITY (US) | 1989-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | GRM1 1780/4885GRM2 2853/4885GRM4 3291/4885 |
| US-20120213729-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, SLC10A1, HCCS | GRM1 4612/4885GRM2 4801/4885GRM4 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.